# OnCo record melanoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/melanoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "melanoma" ;
  schema:name "Melanoma"@en ;
  schema:description "The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."@en ;
  schema:url <https://onco.cc/cancers/melanoma/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Melanoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q180614> ;
  schema:citation <https://en.wikipedia.org/wiki/Melanoma> ;
  onco:tag "skin", "spike" ;
  onco:related <https://onco.cc/cancers/basal-cell-carcinoma/>, <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/pairings/io-first-then-braf-mek/>, <https://onco.cc/pairings/neoadjuvant-io-response-adapted/>, <https://onco.cc/pairings/lag3-adjuvant-caution/>, <https://onco.cc/pairings/io-then-til/>, <https://onco.cc/pairings/oncolytic-plus-pd1/>, <https://onco.cc/pairings/vaccine-plus-pd1/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/til-therapy/>, <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/tcr-t/>, <https://onco.cc/technologies/mistletoe-extracts/>, <https://onco.cc/technologies/gerson-therapy-detox-regimens/>, <https://onco.cc/technologies/dermoscopy-ai/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/kit/>, <https://onco.cc/targets/gp100/>, <https://onco.cc/targets/mage-a4/>, <https://onco.cc/targets/prame/> ;
  onco:drugs <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/drugs/brenetafusp/>, <https://onco.cc/drugs/fianlimab/>, <https://onco.cc/drugs/caris-mi-cancer-seek/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/tasonermin/> ;
  onco:companies <https://onco.cc/companies/microbiotica/>, <https://onco.cc/companies/philogen-s-p-a/>, <https://onco.cc/companies/bioinvent-international/>, <https://onco.cc/companies/multitude-therapeutics/>, <https://onco.cc/companies/neonc-technologies/>, <https://onco.cc/companies/shanghai-kechow-pharma/>, <https://onco.cc/companies/aura-biosciences/>, <https://onco.cc/companies/georgiamune/>, <https://onco.cc/companies/hangzhou-hanx-biopharmaceuticals/>, <https://onco.cc/companies/ionctura/>, <https://onco.cc/companies/krystal-biotech/>, <https://onco.cc/companies/mabxience-research-s-l/>, <https://onco.cc/companies/scancell/>, <https://onco.cc/companies/vyriad/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/immunocore/>, <https://onco.cc/companies/iovance/>, <https://onco.cc/companies/replimune/>, <https://onco.cc/companies/moderna/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/immatics/>, <https://onco.cc/companies/swog/>, <https://onco.cc/companies/ecog-acrin/> ;
  onco:institutions <https://onco.cc/institutions/nki/>, <https://onco.cc/institutions/moffitt/>, <https://onco.cc/institutions/ucla-jonsson/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/melanoma-signalling/> ;
  onco:terms <https://onco.cc/terms/breslow-thickness/>, <https://onco.cc/terms/ulceration-melanoma/>, <https://onco.cc/terms/major-pathological-response/>, <https://onco.cc/terms/hla-a02-restriction/>, <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/nct06697301/>, <https://onco.cc/trials/nct05155254/>, <https://onco.cc/trials/nct05732805/>, <https://onco.cc/trials/nct05751928/>, <https://onco.cc/trials/nct06743126/>, <https://onco.cc/trials/nct06624644/>, <https://onco.cc/trials/seacraft-2/>, <https://onco.cc/trials/nct06054555/>, <https://onco.cc/trials/nct06581406/>, <https://onco.cc/trials/nct06246916/>, <https://onco.cc/trials/nct05727904/>, <https://onco.cc/trials/nct04674683/>, <https://onco.cc/trials/nct06640530/>, <https://onco.cc/trials/nct05608291/>, <https://onco.cc/trials/nct05625399/>, <https://onco.cc/trials/nct02362594/>, <https://onco.cc/trials/nct05270044/>, <https://onco.cc/trials/nct04099251/>, <https://onco.cc/trials/nct05022901/>, <https://onco.cc/trials/nct05549297/>, <https://onco.cc/trials/nct04657991/>, <https://onco.cc/trials/nct05987332/>, <https://onco.cc/trials/nct02938299/>, <https://onco.cc/trials/nct03567889/>, <https://onco.cc/trials/nct07221734/>, <https://onco.cc/trials/checkmate-915/>, <https://onco.cc/trials/keynote-006/>, <https://onco.cc/trials/relativity-047/>, <https://onco.cc/trials/nadina/>, <https://onco.cc/trials/swog-s1801/>, <https://onco.cc/trials/keynote-716/>, <https://onco.cc/trials/combi-ad/>, <https://onco.cc/trials/columbus/>, <https://onco.cc/trials/dreamseq/>, <https://onco.cc/trials/c-144-01/>, <https://onco.cc/trials/imcgp100-202/>, <https://onco.cc/trials/mslt-ii/>, <https://onco.cc/trials/prism-mel-301/>, <https://onco.cc/trials/fianlimab-phase3-melanoma/>, <https://onco.cc/trials/relativity-098/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-esteva-skin-cancer-deep-learning-nature-2017/> ;
  onco:journals <https://onco.cc/journals/melanoma-research/>, <https://onco.cc/journals/pigment-cell-and-melanoma-research/> ;
  onco:pipeline <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/drugs/tebentafusp/>, <https://onco.cc/drugs/ceralasertib/>, <https://onco.cc/drugs/darovasertib/>, <https://onco.cc/drugs/eik1001/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/io102-io103/>, <https://onco.cc/drugs/bcd-217/>, <https://onco.cc/drugs/cobolimab/>, <https://onco.cc/drugs/bcd-100/>, <https://onco.cc/drugs/ima203/>, <https://onco.cc/drugs/lns8801/>, <https://onco.cc/drugs/naporafenib/>, <https://onco.cc/drugs/ibi363/>, <https://onco.cc/drugs/t3011/>, <https://onco.cc/drugs/trk-950/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/gc101-til/>, <https://onco.cc/drugs/ba3071/>, <https://onco.cc/drugs/env-501/>, <https://onco.cc/drugs/enb003/>, <https://onco.cc/drugs/prtx007/>, <https://onco.cc/drugs/au-007/>, <https://onco.cc/drugs/or502/>, <https://onco.cc/drugs/doc1021/>, <https://onco.cc/trials/interpath-001/>, <https://onco.cc/drugs/brenetafusp/>, <https://onco.cc/trials/prism-mel-301/>, <https://onco.cc/targets/prame/>, <https://onco.cc/drugs/fianlimab/>, <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-melanoma/>, <https://onco.cc/ideas/idea-prame-tcr-beyond-a02/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/dermoscopy-ai/>, <https://onco.cc/pairings/neoadjuvant-io-response-adapted/>, <https://onco.cc/technologies/immuno-pet/>, <https://onco.cc/technologies/tcr-t/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/trials/checkmate-067/>, <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/tebentafusp/>, <https://onco.cc/technologies/dermoscopy-ai/>, <https://onco.cc/terms/breslow-thickness/>, <https://onco.cc/terms/ulceration-melanoma/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/trials/mslt-ii/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/trials/keynote-716/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/nadina/>, <https://onco.cc/trials/swog-s1801/>, <https://onco.cc/trials/combi-ad/>, <https://onco.cc/terms/major-pathological-response/>, <https://onco.cc/trials/combi-ad/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/trials/relativity-098/>, <https://onco.cc/trials/checkmate-067/>, <https://onco.cc/trials/relativity-047/>, <https://onco.cc/trials/keynote-006/>, <https://onco.cc/trials/dreamseq/>, <https://onco.cc/pairings/io-first-then-braf-mek/>, <https://onco.cc/trials/columbus/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/pairings/braf-plus-mek/>, <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/trials/c-144-01/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/trials/prism-mel-301/>, <https://onco.cc/drugs/brenetafusp/>, <https://onco.cc/drugs/tebentafusp/>, <https://onco.cc/trials/imcgp100-202/>, <https://onco.cc/terms/hla-a02-restriction/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/technologies/sbrt/> .